Past Events

2019 Annual Public Meeting

Annual Public Meeting Set for May 2, 2019

Collecting Data from EA Treatment for Regulatory Submissions Presentation

Executive Director June Wasser will present Collecting Data from EA Treatment for Regulatory Submissions at the Life Science Compassionate Access Summit at 4:00 pm, Monday, March 18th in Philadelphia.

2018 Innovations in Regulatory Science Awards Dinner

The Reagan-Udall Foundation for the FDA honored two longtime U.S.

Leveraging Real-World Treatment Experience from EA Protocols

See Event Highlights and Download the Meeting Report 

Expanded Access Programs and Real-World Evidence: Public Meeting

Expanded access programs, sometimes also called “compassionate use” programs, provide patients with serious or immediately life-threatening diseases or conditions access to investigational products outside of clinical tria

FDA Launches Rare Disease Framework Initiative to Modernize Small-Cohort Trial Design

To begin shaping the detailed regulations, revised guidances, and internal reviewer training modules, the FDA will convene a major public stakeholder summit on October 28 at its White Oak headquarters in Silver Spring, Maryland, facilitated by the Reagan-Udall Foundation.

Special Seminar: An Interactive Session Offering Expert Insight on Engaging Potential Research Support

As an appointee to the board of the FDA’s Reagan-Udall Foundation, Ed joins a high-profile list of life sciences leaders including former FDA Commissioners, global biotech executives and CMS health policy administrators.

FDA Awards $2.51 Million Contract That Includes Cannabis Public Health Messaging Campaign

The contract was awarded last week to the Reagan-Udall Foundation for the FDA for $2,510,454. The Reagan-Udall Foundation is also expected to produce a white paper and communications report summarizing the stakeholder process and testing results and outlining potential communication strategies for FDA and the U.S. Department of Health and Human Services.

Longevity Drugs Need Endpoints That Predict Clinical Benefit

Candidate measures that could be linked to the biology of aging were discussed at a May 2026 public meeting convened by the Reagan-Udall Foundation for the FDA with the Advanced Research Projects Agency for Health.

BRC Therapeutics Joins FDA And EMA Regulators At Workshop Advancing The Future Of Botanical Drug Development

The workshop also builds on an invitation-only botanical drug development roundtable that the FDA's Center for Drug Evaluation and Research convened with the Reagan-Udall Foundation for the FDA.